Last: | $70.91 |
---|---|
Change Percent: | 0.29% |
Open: | $71.1 |
Close: | $70.91 |
High: | $71.36 |
Low: | $70.79 |
Volume: | 97,178 |
Last Trade Date Time: | 04/18/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$70.91 | $71.1 | $70.91 | $71.36 | $70.79 | 97,178 | 04-18-2024 |
$71.31 | $71.65 | $71.31 | $71.705 | $71.19 | 141,889 | 04-17-2024 |
$71.61 | $71.3 | $71.61 | $71.87 | $71.15 | 149,416 | 04-16-2024 |
$71.12 | $71.33 | $71.12 | $71.9 | $70.86 | 369,619 | 04-15-2024 |
$71.42 | $72.39 | $71.42 | $72.39 | $71.225 | 261,880 | 04-12-2024 |
$72.68 | $72.59 | $72.68 | $73.16 | $72.33 | 118,845 | 04-11-2024 |
$72.6 | $73.02 | $72.6 | $73.69 | $72.58 | 124,892 | 04-10-2024 |
$73.89 | $73.62 | $73.89 | $73.89 | $73.45 | 178,267 | 04-09-2024 |
$73.7 | $73.63 | $73.7 | $74.07 | $73.4 | 103,708 | 04-08-2024 |
$73.76 | $73.39 | $73.76 | $74.13 | $73.31 | 160,245 | 04-05-2024 |
$72.88 | $73.3 | $72.88 | $73.62 | $72.85 | 115,470 | 04-04-2024 |
$73.02 | $73.5 | $73.02 | $73.5 | $72.5 | 205,062 | 04-03-2024 |
$73.83 | $73.83 | $73.83 | $73.88 | $73.05 | 238,585 | 04-02-2024 |
$73.94 | $74.44 | $73.94 | $74.44 | $73.67 | 127,709 | 04-01-2024 |
$73.35 | $73.15 | $73.35 | $73.81 | $73.04 | 157,503 | 03-29-2024 |
$73.35 | $73.15 | $73.35 | $73.81 | $73.04 | 157,503 | 03-28-2024 |
$72.31 | $72.91 | $72.31 | $73.27 | $72.19 | 155,470 | 03-27-2024 |
$72.8 | $73.4 | $72.8 | $73.61 | $72.78 | 144,802 | 03-26-2024 |
$73.41 | $73.22 | $73.41 | $73.56 | $73.02 | 164,698 | 03-25-2024 |
$73.48 | $73.5 | $73.48 | $74.19 | $73.48 | 209,239 | 03-22-2024 |
News, Short Squeeze, Breakout and More Instantly...
Dr. Reddy's Laboratories Ltd Company Name:
RDY Stock Symbol:
NYSE Market:
Centhaquine is a first-of-its-kind resuscitative agent to treat hypovolemic shock by increasing stroke volume and cardiac output due to an increase in (preload) venous blood return to the heart and a decrease in (afterload) due to arterial dilatation India is the first global territory where ...
Versavo® (bevacizumab) is indicated for the treatment of several types of cancers including metastatic colorectal cancer, advanced non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, advanced cervical cancer, ovarian cancer and metastatic breast ...
2024-03-04 16:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...